Immunogenic (tum ? ) variants of mouse tumor P815: cloning of the gene of tum ? antigen P91A and identification of the tum ? mutation, Proc. Natl. Acad. Sci. USA, vol.85, p.2274, 1988. ,
The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68, J. Exp. Med, vol.185, p.695, 1997. ,
Immunity to methylcholanthrene-induced sarcomas, J. Natl. Cancer Inst, vol.18, p.769, 1998. ,
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma, Science, vol.269, p.1281, 1995. ,
High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene, J. Immunol, vol.164, p.6057, 2000. ,
Immunotherapy and gene therapy of cancer, Cancer Res, vol.51, p.5074, 1991. ,
Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells, Adv. Immunol, vol.49, p.281, 1991. ,
ras oncogenes in human cancer: a review, Cancer Res, vol.49, p.4682, 1989. ,
Modulation of the immune response and tumor growth by activated Ras, Leukemia, vol.13, p.502, 1999. ,
Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21 ras peptide presented by HLA-A*0201, Int. J. Cancer, vol.61, p.389, 1995. ,
Cytotoxic CD4 ? and CD8 ? T lymphocytes, generated by mutant p21 ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation, Int. J. Cancer, vol.72, p.784, 1997. ,
Generation of stable CD4 ? and CD8 ? T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations, Cell. Immunol, vol.182, p.137, 1997. ,
Identification of a human CD8 ? T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele, Cell. Immunol, vol.187, p.103, 1998. ,
Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allelespecific amplification (MASA), Oncogene, vol.10, p.1441, 1995. ,
Development, multiplexing, and application of ARMS tests for common mutations in the CFTR gene, Am. J. Hum. Genet, vol.51, p.251, 1992. ,
High incidence of N and K-ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis, Hum. Mutat, vol.18, p.281, 2001. ,
URL : https://hal.archives-ouvertes.fr/hal-01595830
DNA sequencing with chainterminating inhibitors, Proc. Natl. Acad. Sci, vol.74, p.5463, 1977. ,
Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex, Nature, vol.355, p.641, 1992. ,
Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure, Proc. Natl. Acad. Sci, vol.84, p.3365, 1987. ,
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J. Exp. Med, vol.178, p.489, 1993. ,
Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes, Methods, vol.12, p.125, 1997. ,
Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes, Int. J. Cancer, vol.78, p.209, 1998. ,
Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding ras mutation, Lancet, vol.346, p.1399, 1995. ,
p21 ras -peptide-specific T-cell responses in a patient with colorectal cancer: CD4 ? and CD8 ? T cells recognize a peptide corresponding to a common mutation (13Gly3 Asp), Int. J. Cancer, vol.56, p.40, 1994. ,
CD8 ? T cells from a patient with colon carcinoma, specific for a mutant p21 ras -derived peptide (Gly133 Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation, Cancer Immunol. Immunother, vol.40, p.165, 1995. ,
Differential binding to frequent HLA-A alleles of p21 ras derived peptides bearing oncogenic substitutions at position 12 or 13, Hum. Immunol, vol.55, p.117, 1997. ,
A Ras by any other name, Mol. Cell. Biol, vol.21, p.1441, 2001. ,
Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi, J. Med. Genet, vol.36, p.610, 1999. ,
, Prevalence of ras mutations in thyroid neoplasia, vol.50, p.529, 1999.
Developing recombinant and synthetic vaccines for the treatment of melanoma, Curr. Opin. Oncol, vol.11, p.50, 1999. ,
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor, N. Engl. J. Med, vol.333, p.1038, 1995. ,
Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein, J. Exp. Med, vol.191, 1945. ,
Cytotoxic T lymphocyte priming versus cytotoxic T lymphocyte tolerance induction: a delicate balancing act involving dendritic cells, Haematologica, vol.84, p.26, 1999. ,
A mouse mutant p53 product recognized by CD4 ? and CD8 ? T cells, Proc. Natl. Acad. Sci. USA, vol.91, p.3171, 1994. ,
Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides, Nat. Med, vol.1, p.1179, 1995. ,
Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides, Eur. J. Immunol, vol.27, p.798, 1997. ,
Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma, Proc. Natl. Acad. Sci. USA, vol.94, p.6375, 1997. ,
Eradication of established tumors by CD8 ? T cell adoptive immunotherapy, Immnunity, vol.13, p.265, 2000. ,